Advisors Preferred’s Emergent Biosolutions EBS Stock Holding History

Advisors Preferred’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,130	Closed	-$171K	–	192
2021 Q1	$171K	Sell	2,130 -5,755	-73%	-$589K	0.02%	127
2020 Q4	$734K	Buy	7,885 +2,219	+39%	+$204K	0.14%	95
2020 Q3	$585K	Buy	+5,666	New	+$611K	0.12%	49

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Preferred's EBS Position: Q2 2021 in Review

Advisors Preferred sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 2,130 shares — an estimated $171K sold.

Advisors Preferred first reported a position in EBS in Q3 2020 and held it in 3 quarters. The position peaked at $734K in Q4 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Advisors Preferred reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Advisors Preferred sold 2,130 Emergent Biosolutions shares in Q2 2021, an estimated $171K.
Advisors Preferred first reported a position in Emergent Biosolutions in Q3 2020 and held it in 3 quarters.
Advisors Preferred's Emergent Biosolutions position peaked at $734K in Q4 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Advisors Preferred's 13F filing for Q2 2021, filed 26 Jul 2021.